caa a22 4500 605491003 CHVBK 20210128100507.0 cr unu---uuuuu 210128e20150601xx s 000 0 eng 10.1007/s10147-014-0750-y doi (NATIONALLICENCE)springer-10.1007/s10147-014-0750-y Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites [Elektronische Daten] [Tetsuya Ito, Norio Hanafusa, Satoru Iwase, Eisei Noiri, Masaomi Nangaku, Keiichi Nakagawa, Kiyoshi Miyagawa] Background: It is expected that cell-free and concentrated ascites reinfusion therapy (CART) will relieve the symptoms caused by ascites. To date, however, no report of objective changes in patients' symptoms has been published. We have therefore evaluated symptom management by CART. Methods: From April 2011 to July 2012, 37 patients at our hospital, most of whom had malignancies, received CART. Symptom severity was evaluated in each patient 24 h before and after the first CART procedure using a numerical rating scale for abdominal tension and the Japanese version of the M. D. Anderson Symptom Inventory (MDASI-J) for various symptoms. Results: CART significantly improved the scores for abdominal tension and the symptom and interference scores of the MDASI-J within 24 h of the procedure. The abdominal tension scores decreased from 7.19 to 3.81 (p<0.001), the symptom scores of the MDASI-J decreased from 4.73 to 2.75 and the interference scores of the MDASI-J decreased from 7.05 to 5.12. Detailed investigation revealed many symptoms, including fatigue and gastric symptoms, which are the usual targets of paracentesis, as well as general symptoms. No significant correlation between improved scores and the amount of reinfused protein or ascites removed was observed. Patients experienced no severe adverse event. Conclusions: Among the 37 patients receiving CART, various symptoms related to malignant ascites, especially fatigue, improved within the 24-h period following CART. Factors that ameliorate these symptoms remain to be elucidated. Japan Society of Clinical Oncology, 2014 Cell-free and concentrated ascites reinfusion therapy nationallicence Numerical rating scale nationallicence Ascites nationallicence Malignancy nationallicence Symptom relief nationallicence MDASI-J nationallicence Ito Tetsuya Department of Palliative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut Hanafusa Norio Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut Iwase Satoru Department of Palliative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut Noiri Eisei Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut Nangaku Masaomi Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut Nakagawa Keiichi Department of Palliative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut Miyagawa Kiyoshi Laboratory of Molecular Radiology, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 623-628 1341-9625 20:3<623 2015 20 10147 https://doi.org/10.1007/s10147-014-0750-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0750-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ito Tetsuya Department of Palliative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut NATIONALLICENCE 700 1- Hanafusa Norio Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut NATIONALLICENCE 700 1- Iwase Satoru Department of Palliative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut NATIONALLICENCE 700 1- Noiri Eisei Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut NATIONALLICENCE 700 1- Nangaku Masaomi Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut NATIONALLICENCE 700 1- Nakagawa Keiichi Department of Palliative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut NATIONALLICENCE 700 1- Miyagawa Kiyoshi Laboratory of Molecular Radiology, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, 113-8655, Bunkyo-ku, Tokyo, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 623-628 1341-9625 20:3<623 2015 20 10147